SLC6A2 and early-onset autosomal dominant Alzheimer disease: The norepinephrine transporter (NET) is one of the major targets in neuropsychiatric and neurodegenerative diseases like attention deficit hyperactivity disorder (ADHD), depression, Alzheimer’s disease (AD), Parkinson’s disease (PD) and substance abuse [1].